Announcements Trials
Browse Landscape

Phase

Phase 1/2 5Phase 2 3Phase 3 2

Status

Completed 3

Sponsor Class

OTHER 56INDUSTRY 18NIH 5NETWORK 3OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 3

Conditions

Multiple Myeloma 3Recurrence 1

Interventions

Cisplatin 118Radiotherapy 114Cyclophosphamide 93Paclitaxel 84Gemcitabine 74Carboplatin 67Filgrastim 60Doxorubicin 57Vincristine 56Etoposide 56Docetaxel 56Fluorouracil 51Cytarabine 41Prednisone 40Methotrexate 40Leucovorin 39Dexamethasone 37Capecitabine 36Irinotecan 35Rituximab 29Oxaliplatin 28Granulocyte Colony-Stimulating Factor 27Cetuximab 26Bevacizumab 26durvalumab 24Temozolomide 24Radiotherapy, Intensity-Modulated 24Peripheral Blood Stem Cell Transplantation 24Magnetic Resonance Spectroscopy 24Surgical Procedures, Operative 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × NETWORK × carfilzomib × Clear all
NCT01903811 2024-12-20

S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma

SWOG Cancer Research Network

Phase 2 Completed
143 enrolled 14 charts
Plasma cell

Multiple Myeloma, Recurrence

NCT01346787 2023-09-08

CCD

European Myeloma Network B.V.

Phase 2 Completed
58 enrolled
Plasma cell

Multiple Myeloma

NCT02597062 2023-08-28

High-Dose Weekly Carfilzomib Plus Cyclophosphamide and Dexamethasone in the Treatment of Relapsed Multiple Myeloma

Canadian Cancer Trials Group

Phase 2 Completed
76 enrolled 9 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡